anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis is a major cause of mortality among critical patients. Acute kidney injury (AKI) is the common complication in patients with sepsis, characterized by rapid deterioration of renal function. The purpose of this study is to assess the impact of inhaling high concentration hydrogen on septic mice with AKI and to examine the involvement of mitochondria in this process. High concentration hydrogen does not cause hypoxia and can alleviate AKI and improve 7-day survival in septic mice. Inflammatory factors are markedly elevated in the serum and renal tissues in CLP group which are dramatically down-regulated by hydrogen. The activities of both antioxidant enzymes are significantly reduced after CLP, whereas hydrogen markedly increases the activities of SOD and CAT. MMP is found to be significantly lower in CLP group whereas this effect is reversed by hydrogen. The trend of ATP content in renal tissues corresponded with that of MMP. There is a substantial downregulation of PGC-1α, Nrf2, and TFAM protein in CLP group. Drp1 expression is significantly higher in CLP group compared to Sham group, while the opposite trend is observed for MFN2. Hydrogen can reverse these changes. Inhalation of high concentration hydrogen can improve acute kidney injury, 7-day survival, inflammatory response and oxidative stress in septic mice. The mechanism may be related to inhibit renal mitochondrial fission and promote mitochondrial fusion and biogenesis.
The Phase 1 consisted of the dose escalation of enzastaurin in 2 cohorts of up to 6 patients to assess maximum tolerated dose (MTD). Cohort 1 = radiotherapy/enzastaurin 250 mg per day/temozolomide 75 mg/m\^2 therapy. The 6 initial cohort patients were clinically evaluated for dose-limiting toxicities (DLT). If no more than 1 of 6 patients experienced a DLT or tumor progression, patients continued 1 complete adjuvant enzastaurin/temozolomide 28-day cycle. If there was no significant toxicity after the first adjuvant cycle, participants received subsequent adjuvant enzastaurin/temozolomide cycles. If no more than 1 of the 6 initial cohort participants treated at 250 mg of enzastaurin experienced a DLT during radiotherapy and the first adjuvant cycle, up to 6 more participants could be entered at 500 mg of enzastaurin. The Phase 2, using the MTD determined in the Phase 1 (250 mg), evaluated the combination's safety and measured OS.
NEW MATERIAL:A germanium-alkali mixed salt of an organic acid composed of an alkali metal germanate and an organic acid. EXAMPLE:Germanium sodium citrate. USE:A component of herb used as a remedy for cancer, etc. It has excellent absorbability in living body, especially in vegetable because the germanium acts as an organic substance in place of inorganic substance. PREPARATION:An aqueous solution of an alkali metal germanate is produced by boiling germanium oxide and an alkali (e.g. sodium hydroxide) usually in water under agitation. 1mol of the produced alkali metal germanate is made to react with usually >=6 base equivalent of an organic acid (e.g. malic acid, citric acid, etc.).
The perineum consists of skin, muscles and connective tissue. A connective tissue disorder related to POP has been reported in biochemical and molecular studies. OASIS are considered a severe complication of vaginal delivery that may lead to a great deal of morbidity. Familial history is known as a risk factor for OASIS. Currently, there is no established genetic link between connective tissue components and OASIS. Therefore, the investigators assume that studying the genetic predisposition factors of women who experience OASIS, might generate a stronger tool to predict severe occurrence of vaginal laceration. It may also help to consult women before vaginal delivery about the risk of OASIS.

The aim of this study is to find an association between genetic variation and increased risk for OASIS.
Participants will receive oral semaglutide in addition to metformin (in a steady daily dose of ≥1500 mg), starting with an initial dose of 3 mg. The dose of semaglutide will be increased to 7 mg after 30 days, and then to a maintenance dose of 14 mg once daily after another 30 days that will be continued to week 26. In the case of inadequately controlled glycemia (HbA1c \>8.0 % or symptomatic hyperglycemia), rescue treatment with gliclazide will be initiated.
A preparation method of a traditional Chinese medicine oral liquid, a traditional Chinese medicine oral liquid for treating children hyperkinetic syndrome and a preparation method thereof, belonging to the technical field of traditional Chinese medicine oral liquid. The preparation method of the Chinese medicinal oral liquid comprises percolating Chinese medicinal powder to obtain percolate, and making into Chinese medicinal oral liquid. The preparation method avoids heating by percolation method, and retains effective components to the maximum extent. The preparation method of the traditional Chinese medicine oral liquid for treating children hyperkinetic syndrome comprises the step of preparing twelve traditional Chinese medicines including 8-11 parts of prepared rehmannia root, 3-6 parts of glossy privet fruit, 3-5 parts of Chinese yam, 1-3 parts of Chinese magnoliavine fruit, 6-9 parts of dragon bone, 2-5 parts of polygala tenuifolia, 3-5 parts of grassleaf sweelflag rhizome, 1-3 parts of common anemarrhena rhizome, 2-5 parts of amur corktree bark, 2-4 parts of tree peony bark, 2-5 parts of oriental waterplantain rhizome and 2-5 parts of Indian buead into. The preparation method has simple and rapid process, and accords with the theory of traditional Chinese medicine. In addition, the invention also relates to a traditional Chinese medicine oral liquid for treating children's attention deficit hyperactivity disorder.
The invention discloses a traditional Chinese medicine decoction used for treating common cold, and a preparation method thereof. The decoction is prepared from the raw materials of Chinese thorowax root, cassiabarktree twig, incised notopterygium rhizome and root, Siberian solomonseal rhizome, sweet potato leave, rhubarb, Chinese ephedra herb, American ginseng, radix notoginseng, tendrilleaf fritillary bulb, Chinese magnoliavine fruit, biod magnolia flower bud, angelica archang lica, pinellia tuber (processed with ginger), Baikal skullcap root, salvia miltiorrhiza, ginger root, elephantopus scaber, sweet potato leave, white peony root, lotus seed, creeping liriope, tartarian aster, balloonflower root, obtuseleaf senna seed, and loquat leaf. The raw materials are well mixed according to a certain weight ratio, the mixture is decocted with water for 20-30min, and a prepared decoction can be taken. The traditional Chinese medicine composition provided by the invention has reasonable formula. With the traditional Chinese medicine, metabolism can be effectively promoted, blood circulation can be enhanced, human body basic physique can be enhanced, common cold can be treated effectively, and a curative effect is substantial. The decoction is easy to take, and causes no toxic or side effect.
The utility model relates to a visual dual regulated drug paste for treatment hyperplasia and sunken scar. This drug paste includes a glue paste, an impervious layer bonded in the middle of the glue paste, an ointment layer adhered to the impervious barrier and a paper paste agglutinated in the ointment layer and the glue paste. An observation window is provided in the impervious layer of the glue paste. The impervious layer is made of transparent material, through which, the symptom of the scar tissue surface with medicine can be observed and the affected part can be handled promptly. This drug paste has the advantages of usability and reliability. The effective component of this medicament can stay longer, which can facilitate the absorption by the scar tissue. The product is considered as an ideal cicatricle drug paste.
Tagged writing receivers, such as surface-based devices, include identity codes that identify the tagged writing receiver. The tagged writing receiver has content written on it in real-time and digitally saved in real-time. An addendum code can be activated by touching a sub-zone of the receiver with a tagged writing instrument to save the content in the sub-zone in a particular authentication database at a network destination, such as a hospital or treatment center. The tagged writing instrument writes on the tagged writing receiver and also captures the content from the tagged writing receiver. The tagged writing instrument also has identity codes that identify the tagged writing instrument. The tagged writing instrument converts the written content into recognized data items for saving.
Chronic inflammation is a significant contributor to hypertensive heart failure. Carnosol (Car), primarily derived from the sage plant (Salvia carnosa), exhibits anti-inflammatory properties in a range of systems. Nevertheless, the influence of angiotensin II (Ang II) on cardiac remodeling remains uncharted. Car was shown to protect mice's hearts against Ang II-induced heart damage at dosages of 20 and 40 mg/kg/d. This protection was evident in a concentration-related decrease in the remodeling of the heart and dysfunction. Examination of the transcriptome revealed that the pivotal roles in mediating the protective effects of Car involved inhibiting Ang II-induced inflammation and the activation of the mitogen-activated protein kinase (MAPK) pathway. Furthermore, Car was found to inhibit p38 phosphorylation, therefore reducing the level of inflammation in cultured cardiomyocytes and mouse hearts. This effect was attributed to the direct binding to p38 and inhibition of p38 protein phosphorylation by Car both in vitro and in vivo. In addition, the effects of Car on inflammation were neutralized when p38 was blocked in cardiomyocytes.
This is a randomized (a sequence of fasted and fed periods accompanying study drug intake will be assigned by chance), open-label (physicians and participants know the identity of the assigned treatment), single-center, single-dose, 2-period, 2-sequence, crossover study of Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg. Approximately 24 healthy adult participants will be enrolled to ensure that at least 20 complete the study.

After a screening period, participants will be randomly assigned to 1 of the 2 treatment sequences (AB or BA) on Day 1 of Period 1. Treatment A means a participant will receive a single 150/1,000 mg CANA/MET XR FDC tablet under fasted conditions, and Treatment B means that a participant will receive the same drug under fed conditions. Participants will need to remain at the study center for 4 days (72 hours postdose) after the drug administration for collection of blood samples in each treatment period. There will be a 10- to 14-day washout period between Period 1 and Period 2. On Day 4 (72 hours postdose) of Period 2, when participants are discharged from the study center, they will be given instructions to return for a follow-up visit 7 to 10 days later. For Treatment B (in fed state), participants will be provided with a standardized high-fat breakfast. Participants' safety will be monitored throughout the study.
Breast cancer is a common malignant disease that threatens the health of women. As a serious complication of breast cancer treatment, lymphedema is caused by chronic accumulation of lymph fluid in the interstitial spaces of the affected limb or surrounding areas. Reported prevalence of lymphedema following treatment for breast cancer varies, ranging from 7-45%. One reason for the wide variation in the reported incidence of lymphedema is the different measurement techniques used and the absence of an agreed diagnostic criteria. Nowadays, the common method include limb circumference measurement、volume measurement、bioimpedance spectroscopy (BIS) and self-report. Each of these methods has advantages and disadvantages. A variety of publications have demonstrated the ability of bioimpedance to diagnose subclinical lymphedema. As a new method for detecting lymphedema, some study have also shown indocyanine green（ICG）lymphography can have a certain value for the detection of subclinical lymphedema. Early detection can reduce the incidence of late-stage lymphedema in postoperative patients. Therefore, we want to explore the ability of these methods. We are going to perform baseline arm circumference measurements and bioelectrical impedance measurements for all preoperative breast cancer patients in our center. In addition, the arm circumference measurement、volume measurement、bioimpedance spectroscopy (BIS) 、self-report and indocyanine green (ICG) lymphography will be performed on patients who go to the lymphedema clinic after breast cancer surgery.First, we want to establish the threshold and reference value range based on the impedance value of patients with lymphedema and people without lymphedema.Second, we are going to examine the relationship between the most commonly used methods of lymphedema and also to test which method is more sensitive for the diagnosis of clinical and subclinical lymphedema. Finally, we want to explore the ability of ICG lymphography in detecting sub-clinical lymphedema.
A self-sterilizing propellant for aerosol dispensers charged under an initial pressure of 15-100 p.s.i.g. comprises a non-reactive, non-toxic gas, e.g. carbon dioxide, nitrogen, a halogenated hydrocarbon containing one or more fluorine atoms, and 40-1000 parts per million of an alkylene oxide.  Tests are described involving B. subtilis spores and aerosol formulations of Furacin-5-nitro-2-furaldehyde semicarbazone-in hexyleneglycol and polyethylene glycol, with trichloromonofluoromethane and a mixture of monochlorodifluoroethane and ethylene oxide.ALSO:A self-sterilizing propellant for aerosol dispensers of pharmaceutical topical preparations charged under an initial pressure of 15-100 p.s.i.g. comprises a non-reactive, non-toxic gas, e.g., carbon dioxide, nitrogen, a halogenated hydrocarbon containing one or more fluorine atoms, and 40-1000 parts per million of an alkylene oxide.  Tests are described involving B.subtilis spores and aerosol formulations of Furacin-5 - nitro - 2 - furaldehyde semicarbazone-in hexylene glycol and polyethylene glycol, with trichloromonofluoromethane and a mixture of monochlorodifluoroethane and ethylene oxide.
The invention belongs to the field of pharmacy, and relates to an application of a TCM monomer of apigenin to prepare a medicine for treating the pancreatic cancer. A CCK-8 method for evaluation, repeated screening and optimization, and a pharmacodynamic test for inhibiting proliferation of pancreatic cancer SW1990 cells are adopted to screen an effective monomer, having a strong anti-tumor effect, of apigenin. Moreover, an equipment of apigenin for interfering a Sonic Hedgehog signal channel of human pancreatic cancer SW1990 stem cells is carried out. The result shows that apigenin can obviously inhibit proliferation of pancreatic cancer stem cells, lower the ratio of pancreatic cancer stem cells, and reduce self-renewable ability of pancreatic cancer stem cells. The ratio of CD24+CD44+ cells is obviously lowered through flow cytometry; the amount of cancer stem cells cultured free of serum decreases; and expression of members in the Sonic Hedgehog signal channel at mRNA and protein levels is obviously lowered. The TCM monomer of apigenin can be taken as an individual unique active component for preparing the medicine for treating the pancreatic cancer.
This is a randomized, observer-blind, placebo-controlled trial enrolling third-trimester pregnant women in the Northern and Southern hemispheres, for up to four consecutive RSV seasons in each hemisphere. The trial will enroll 4636 third-trimester pregnant subjects. Women in the third trimester of a singleton uncomplicated pregnancy and 18 to 40 years of age (inclusive) will be enrolled and randomized in a 1:1 ratio into one of two treatment groups, active or placebo, over approximately the three months prior to peak RSV season. After the first global season of enrollment, the randomization scheme will be changed to a 2:1 (active/placebo) ratio to enable more efficient accrual of the safety database.

All maternal subjects will receive a single intramuscular (IM) injection on Day 0 with the assigned test article, the RSV F vaccine or placebo. Study participation for maternal subjects will span approximately nine (9) months from the first dose, ending six (6) months post-delivery. Study follow-up for infant subjects who are consented will span approximately one (1) year post-delivery.
Subjects will receive 130 hours of HABIT-ILE performed in two intervention periods as camp format for 6,5-hours/day, 5 days/week for two weeks. Each intervention period will be 6-months apart.
BACKGROUND: This study aimed to investigate the value of nonenhanced computed tomography (CT)-based radiomics in determining disease progression in breast cancer patients with bone marrow metastases and to develop a model for assessing treatment efficacy.
METHODS: A total of 134 breast cancer patients with bone metastases were enrolled from three hospitals. Nonenhanced CT was performed after two cycles of drug treatment. The images were categorized into an invalid and a valid group according to disease progression status. The largest osteolytic lesions' maximum cross-sections in the CT images were selected as regions of interest (ROIs) for feature extraction. Variance threshold, SelectKBest, and least absolute shrinkage and selection operator (LASSO) were used to reduce feature dimensionality. K-nearest neighbor algorithm (KNN), support vector machine (SVM), extreme gradient boosting (XGBoost), random forest (RF), logistic regression (LR), and decision tree (DT) algorithms were trained to establish radiomics models. Receiver operating characteristic (ROC) curves were generated to evaluate the diagnostic performance of the models.
RESULTS: The KNN classifier demonstrated the best performance compared to the random grouping method. In the validation group, the area under the ROC curve (AUC) was 0.810. In the cross-validation method, the RF classifier showed the best performance with an AUC of 0.84.
CONCLUSION: Nonenhanced CT-based radiomics provides a promising method for evaluating the efficacy of systemic drug therapy in breast cancer patients with osteolytic bone metastases.
PROBLEM TO BE SOLVED: To obtain the subject vaccine high in efficacy and safety, maximally suppressing the local reaction tending to come about when inoculated into the human body while retaining its excellent antibody productivity by including an oil component, emulsifier and specific aqueous component. SOLUTION: This oil adjuvant vaccine is obtained by including (A) 10-90 wt.% of an oil component liquid at normal temperatures (ester derived from an alcohol and fatty acids pref. including >=85 wt.% of cis-Δ9-octadecenoic acid and >=90 wt.% of cis-Δ9-unsaturated fatty acid), (B) 0.5-30 wt.% of an emulsifier selected from nonionic surfactants (pref. e.g. glycerol monooleate, ethylene oxide 20-60 mol adduct of hydroxyfatty acid triglyceride), and (C) 0.1-30 wt.% of an aqueous component containing a polyethylene glycol pref. 300-20,000 in average molecular weight and biologically acceptable effective amounts of antigen.
Described herein are variations of a medicament-producing implantable matrix for the treatment of chronic diseases. For example, an implantable matrix may include a cell-coated a human acellular vessel-based vascular graft. The cells may be engineered to produce medicaments capable of treating a chronic disease. A cell-seeded matrix may be implanted adjacent to a patient's blood vessel such that the medicaments produced by the cells are easily released into the patient's blood stream. Additionally, or alternatively, a cell-seeded matrix may treat chronic disease at an environment local to an implantation site. Also described herein are methods for making and use of such implantable matrices.
ESWT will be applied to Group 1 once a week for a total of 3 weeks. Modus ESWT device will be used. The patient's wrist will be applied at a pressure of 4 bar and 2000 Hz at a frequency of 5 Hz. Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
<P>PROBLEM TO BE SOLVED: To provide a new mineral-filled soap mild to a skin and feeding nutrition to the skin.  <P>SOLUTION: This mineral-filled soap comprises a soap substrate, a humic shale (humus shale) extract, a herbal medicine extract and ceramide. The herbal medicine extract is preferably a mixture of liquids containing the herbal medicine component extracted by dipping glycyrrhiza, a sophora root and a coix seed in an alcohol or butylene glycol for 2-3 weeks. The mineral-filled soap can be made by mixing a desired amount of the humic shale extract, the herbal medicine extract and ceramide with the heated, liquified soap substrate, casting the resulting mixture, standing it to cool and solidify, and decasting it. The mineral-filled soap can also be made by mixing a required amount of the humic shale extract with an emulsified reaction product that is produced by saponification of a heated vegetable oil with an aqueous caustic soda solution under enough agitation, casting the mixture into a mold, standing it to cool and solidify, and demolding it.  <P>COPYRIGHT: (C)2008,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide such a gene-transferring material that a vector therein stays at a site after the material is embedded in the specific site in vivo.  <P>SOLUTION: The gene-transferring material is such that a conjugate composed of a nucleic acid and a vector consisting of a branched chain-bearing cationic polymer is held in a porous form consisting of a synthetic resin with communicating three-dimensional porous network structure, wherein the vector is preferably such that 3, 4 or 6 branched chains are bound to a benzene ring. Specifically, this gene-transferring material is obtained by impregnating the above conjugate in a thin-rod form of soft-segmented polyurethane. In this gene-transferring material, the nucleic acid is e.g. an HGF (hepatocyte growth factor).  <P>COPYRIGHT: (C)2008,JPO&INPIT
Early detection of local recurrence has been shown to improve survival. What is unclear is how frequently mammography should be performed, how long surveillance should continue and how the answers to these questions vary with tumour pathology, patients age, and surgery type. Many of these questions are not directly answerable from the current literature. While some of these questions will be answered by the Mammo-50 study, evidence from local recurrence rates, tumour biology, and the lead time of mammography can be used to guide policy. Young age is the strongest predictor of local recurrence and given the short lead time of screening in women under 50, these women require annual mammography. Women over 50 with HER-2 positive and triple negative breast cancer have higher rates of local recurrence after breast conserving surgery than women with luminal cancers. Women with HER-2 positive and triple negative breast cancer also have a higher rate of recurrence in years 1-3 post surgery. Annual mammography in year 1-4 would appear justified. Women over 50 with luminal cancers have low rates of local recurrence and no early peak. Recurrence growth will be low due to tumour biology and hormone therapy. Biennial mammography after year 2 would seem appropriate. Women over 50 following mastectomy have no early peak in contralateral cancers so the frequency should be determined by the lead time of screening. This would suggest 2 yearly mammography for women aged 50-60 while 3 yearly mammography may suffice for women over 60.